What are people's views on the A-share market performance on October 19, 2026?

1. The market is concerned about AI-related debt financing. The trigger was CoreWeave—a major NVIDIA cloud service provider—facing mounting debt pressure, causing its stock price to plunge sharply! This has further intensified market concerns over the credit market. 2. Anthropic, a leading large-model company, saw its valuation slashed. Its latest Q3 financial report showed $16.8 billion in revenue and a 45% growth rate—below prior optimistic expectations—disappointing some investors. Currently, some investors are considering lowering its IPO valuation from $200 billion to $150 billion—effectively a 25% discount. Moreover, ChangXin Memory Technologies’ technological progress has raised questions about the long-term scarcity of overseas memory industry leaders! Recently, the memory sector has suffered the steepest declines. 3. International oil prices surged sharply, reigniting fears of inflation and interest-rate hikes. On Friday, international oil prices rose over 3%, with Brent crude surging close to $110 per barrel. The shadow of a Federal Reserve rate hike has once again loomed over markets, prompting expectations that the Fed may raise rates by 50 basis points in December!

International top pharmaceutical companies’ weekly global regulatory approvals, licensing & partnership deals, M&A activities, clinical developments, and financial performance—September 28 to October 4, 2026

• Eli Lilly: On October 2, Eli Lilly announced that the U.S. FDA has approved Jaypirca (pirtobrutinib, 100 mg and 50 mg tablets)—a non-covalent Bruton’s tyrosine kinase (BTK) inhibitor—for an expanded indication to treat adult patients with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) without known 17p deletion. This approval enables Jaypirca to be used as a first-line therapy for eligible patients. The Jaypirca label includes warnings and precautions regarding infections, bleeding, cytopenias, arrhythmias, second primary malignancies, hepatotoxicity (including drug-induced liver injury), and embryo-fetal toxicity. The approval was based on preliminary results from the BRUIN CLL-313 clinical trial, presented at the American Society of Hematology Annual Meeting and Exposition and published in the Journal of Clinical Oncology. With a median follow-up of 28 months, progression-free survival (PFS)—the primary endpoint—was significantly superior in the trial group (n=141) versus the bendamustine plus rituximab control group (n=141) (hazard ratio = 0.20); median PFS had not yet been reached in the trial group, whereas it was 33.5 months in the control group. Overall response rate (ORR) was 94% in the trial group (13% complete response [CR], 81% partial response [PR]), versus 81% in the control group (21% CR, 60% PR). Serious adverse reactions occurring in ≥3% of patients included pneumonia (5%). • Novo Nordisk: On October 3, Novo Nordisk announced that the U.S. FDA informed the company that the Biologics License Application (BLA) for denecimig—intended for adults and children with hemophilia A (with or without inhibitors)—remains under review. Novo Nordisk submitted the BLA to the U.S. FDA in September 2025, originally expecting a decision in Q3 2026. Following submission, the FDA conducted a pre-approval inspection of the manufacturing site and issued feedback. The FDA notified Novo Nordisk that ongoing remediation efforts at the manufacturing site are the reason for the extended review timeline. Novo Nordisk is actively implementing corrective actions per FDA feedback and closely collaborating with regulators to resolve remaining outstanding items. Denecimig is an FVIIIa-mimetic bispecific antibody designed to provide prophylactic treatment against bleeding episodes for patients with hemophilia A—with or without inhibitors—at dosing frequencies of once monthly, once every two weeks, or once weekly. It is administered subcutaneously and functions by bridging factor IXa and factor X, thereby mimicking activated coagulation factor VIII (FVIIIa) activity to restore thrombin generation and support blood clotting. • Abbott: On September 30, Abbott announced the U.S. commercial launch of its SimpleScreen CRC test for colorectal cancer (CRC) screening. This test—approved by the U.S. FDA—is a blood-based CRC screening tool intended for adults aged 45 years and older who are at average risk for the disease.

Kronos Worldwide Announces Q3 2026 Earnings Release Date

Oct 20, 2026

Kronos Worldwide scheduled its third-quarter 2026 financial results for November 5 after market close. Prior second-quarter revenue reached USD 558.1 million, exceeding analyst estimates.

ad-hoc-news.de

2026-04-14

Kronos Worldwide, Inc. Announces Expected First Quarter 2026 Earnings Release Date

2026-04-15

Kronos sets May 6 release for first-quarter results after close

2026-05-04

Kronos Worldwide Reports Q4 2025 Net Loss of $82.8 Million

2026-05-04

Kronos Worldwide Inc Expected to Post Loss of 22 Cents a Share - Earnings Preview

2026-05-06

Kronos Worldwide, Inc. Reports First Quarter 2026 Results